250 related articles for article (PubMed ID: 17048976)
21. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
22. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
23. Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition.
Balcarek J; Sevá Pessôa B; Bryson C; Azizi M; Ménard J; Garrelds IM; McGeehan G; Reeves RA; Griffith SG; Danser AH; Gregg R
Hypertension; 2014 May; 63(5):942-50. PubMed ID: 24470465
[TBL] [Abstract][Full Text] [Related]
24. New approaches to blockade of the renin-angiotensin-aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren.
Ichihara A; Sakoda M; Kurauchi-Mito A; Narita T; Kinouchi K; Bokuda K; Itoh H
J Pharmacol Sci; 2010; 113(4):296-300. PubMed ID: 20675959
[TBL] [Abstract][Full Text] [Related]
25. Reversibility of the effects of aliskiren in the renal versus systemic circulation.
Schneider MP; Janka R; Ziegler T; Raff U; Ritt M; Ott C; Veelken R; Uder M; Schmieder RE
Clin J Am Soc Nephrol; 2012 Feb; 7(2):258-64. PubMed ID: 22173856
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren.
Hong Y; Dingemanse J; Mager DE
Clin Pharmacol Ther; 2008 Jul; 84(1):136-43. PubMed ID: 18288088
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects.
Vaidyanathan S; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2007 Apr; 47(4):453-60. PubMed ID: 17389554
[TBL] [Abstract][Full Text] [Related]
28. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
Sanoski CA
Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
[TBL] [Abstract][Full Text] [Related]
31. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
Stanton A; Jensen C; Nussberger J; O'Brien E
Hypertension; 2003 Dec; 42(6):1137-43. PubMed ID: 14597641
[TBL] [Abstract][Full Text] [Related]
32. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.
Nussberger J; Gradman AH; Schmieder RE; Lins RL; Chiang Y; Prescott MF
Int J Clin Pract; 2007 Sep; 61(9):1461-8. PubMed ID: 17590217
[TBL] [Abstract][Full Text] [Related]
33. Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects.
Ayalasomayajula S; Yeh CM; Vaidyanathan S; Flannery B; Dieterich HA; Howard D; Bedigian MP; Dole WP
J Clin Pharmacol; 2008 Jul; 48(7):799-811. PubMed ID: 18490495
[TBL] [Abstract][Full Text] [Related]
34. Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
Huang HL; Vaidyanathan S; Yeh CM; Bizot MN; Dieterich HA; Dole WP; Howard D
Curr Med Res Opin; 2008 Sep; 24(9):2449-56. PubMed ID: 18662494
[TBL] [Abstract][Full Text] [Related]
35. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.
Khadzhynov D; Slowinski T; Lieker I; Neumayer HH; Albrecht D; Streefkerk HJ; Rebello S; Peters H
Clin Pharmacokinet; 2012 Oct; 51(10):661-9. PubMed ID: 23018529
[TBL] [Abstract][Full Text] [Related]
37. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
Sepehrdad R; Frishman WH; Stier CT; Sica DA
Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
[TBL] [Abstract][Full Text] [Related]
38. [Advantages and limitations of renin inhibition with aliskiren].
Azizi M; Frank M; Steichen O; Blanchard A
Ann Pharm Fr; 2011 May; 69(3):142-50. PubMed ID: 21570538
[TBL] [Abstract][Full Text] [Related]
39. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
Tapaninen T; Karonen T; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2013 Jan; 23(1):19-24. PubMed ID: 23151832
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]